Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema-Reference-Cited by-同舟云学术

Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema

Published:2018-05-05 Issue:8 Volume:55 Page:789-796
ISSN:0940-5429
Container-title:Acta Diabetologica
language:en
Short-container-title:Acta Diabetol

Author:

Busch Catharina^ORCID, ,Zur Dinah,Fraser-Bell Samantha,Laíns Inês,Santos Ana Rita,Lupidi Marco,Cagini Carlo,Gabrielle Pierre-Henry,Couturier Aude,Mané-Tauty Valérie,Giancipoli Ermete,Ricci Giuseppe D’Amico,Cebeci Zafer,Rodríguez-Valdés Patricio J.,Chaikitmongkol Voraporn,Amphornphruet Atchara,Hindi Isaac,Agrawal Kushal,Chhablani Jay,Loewenstein Anat,Iglicki Matias,Rehak Matus

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/article/10.1007/s00592-018-1151-x/fulltext.html

Reference26 articles.

1. Arroba AI, Valverde AM (2017) Modulation of microglia in the retina: new insights into diabetic retinopathy. Acta Diabetol 54(6):527–533. https://doi.org/10.1007/s00592-017-0984-z

2. Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556–564. https://doi.org/10.2337/dc11-1909

3. Nguyen QD, Shah SM, Heier JS et al (2009) Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 116(11):2175–2181. https://doi.org/10.1016/j.ophtha.2009.04.023

4. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR et al (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372(13):1193–1203. https://doi.org/10.1056/NEJMoa1414264

5. Gillies MC, Lim LL, Campain A et al (2014) A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 121(12):2473–2481. https://doi.org/10.1016/j.ophtha.2014.07.002

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VEGF-A165a and angiopoietin-2 differently affect the barrier formed by retinal endothelial cells;Experimental Eye Research;2024-10

2. Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists;Eye;2024-08-30

3. Switching to an Intravitreal Dexamethasone Implant after Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema: A Review;Life;2024-06-03

4. Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: Guidance from a UK panel of retina specialists;2024-04-01

5. Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data;European Journal of Ophthalmology;2024-03-11